Nea Management Company
$1.6B 13F equity value
27 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Nea Management Company covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | 13,222,228 | $247M | 15.5% |
| MBX | MBX Biosciences, Inc. | 3,614,486 | $200M | 12.6% |
| GLUE | Monte Rosa Therapeutics, Inc. | 7,692,298 | $186M | 11.7% |
| CELC | Celcuity Inc. | 1,710,561 | $179M | 11.3% |
| SGP | Spyglass Pharma, Inc. | 7,392,301 | $165M | 10.4% |
| SVRA | Savara, Inc. | 24,471,264 | $151M | 9.5% |
| ZBIO | Zenas BioPharma, Inc. | 4,023,219 | $102M | 6.4% |
| COUR | Coursera, Inc. | 12,867,769 | $73M | 4.6% |
| AUPH | Aurinia Pharmaceuticals, Inc. | 3,969,834 | $67M | 4.2% |
| CRSP | CRISPR Therapeutics AG | 1,058,570 | $58M | 3.6% |
Track Nea Management Company's 13F portfolio: $1.6B in reported holdings, 27 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}